

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kindstar Globalgene Technology, Inc.**  
**康聖環球基因技術有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 9960)**

**INSIDE INFORMATION**  
**PROPOSED ACQUISITION**

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

**PROPOSED ACQUISITION**

Wuhan Kindstar Medical Laboratory Co., Ltd.\* (武漢康聖達醫學檢驗所有限公司) (“**Wuhan Kindstar**”) (a PRC Consolidated Entity (as defined below)) is intended to conditionally acquire, and Hainan Zhixin Technology Partnership (Limited Partnership)\* (海南知心科技合夥企業(有限合夥)) (“**Hainan Zhixin**”), Ms. Wang Ying, Beijing Leading Precision Medical Health Industry Investment Co., Ltd.\* (北京領創精準醫療健康產業投資有限公司) (“**Beijing Leading Precision**”) and Beijing Zhongguancun Development Qihang Industrial Investment Fund (Limited Partnership)\* (北京中關村發展啟航產業投資基金(有限合夥)) (“**Beijing Qihang**”), are intended to sell, in aggregate, 24.47% equity interest in Bestino (Beijing) Medical Technology Co., Ltd.\* (百世諾(北京)醫療科技有限公司) (the “**Target Company**”) at the consideration of approximately RMB37,000,000 (the “**Proposed Acquisition**”). In addition, Wuhan Kindstar is intended to conditionally make cash contribution of approximately RMB66,000,000 in tranches to the Target Company and to subscribe for the capital increase equity. The final consideration is subject to the terms as set out in the transaction documents. As of the date of this announcement, the parties have not entered into any legally binding transaction documents. To the best knowledge, information and belief of the directors of the Company, having made all reasonable enquiry, Hainan Zhixin, Ms. Wang Ying, Beijing Leading Precision, Beijing Qihang and the Target Company as well as the respective ultimate beneficial owners of the aforesaid parties are third parties independent of the Company and its connected persons.

Upon completion of the Proposed Acquisition, the Company will have control over the board of directors of the Target Company, and the Target Company will become a non-wholly owned subsidiary of the Company and its financial results will be consolidated into the consolidated financial statements of the Group.

## **BASIC INFORMATION OF THE RELATED PARTIES**

### **The Company**

The Company is an exempted company with limited liability incorporated under the laws of the Cayman Islands on August 24, 2007. The Group is a leading independent esoteric clinical testing service provider in the People's Republic of China (the "PRC").

### **Wuhan Kindstar**

Wuhan Kindstar is a limited liability company established under the laws of the PRC on August 8, 2003 and a PRC consolidated entity whose financial results have been consolidated and accounted for as subsidiaries of the Company by virtue of variable interest entity structure ("PRC Consolidated Entity"). It is principally engaged in the provision of clinical testing services in the PRC.

### **Target Company**

The Target Company is a limited liability company established under the laws of the PRC in June 2013, which is principally engaged in the testing business of cardiovascular specialty. Through cutting-edge testing technologies such as high-throughput sequencing, fluorescent quantitative polymerase chain reaction (PCR), mass spectrometry and chemiluminescence, the Target Company has carried out molecular diagnosis of more than 300 cardiovascular and cerebrovascular diseases such as sudden cardiac death, and provided personalized medication guidance for more than 200 commonly used drugs such as antihypertensive, lipid-lowering and anticoagulation medication.

### **Hainan Zhixin**

Hainan Zhixin is a limited liability partnership established under the laws of the PRC. It is a shareholding platform. The general partner of Hainan Zhixin is Mr. Liu Gang, and Hainan Zhixin is held as to approximately 40.83% by Mr. Liu Gang and approximately 39.45% by Mr. Lu Xiang.

### **Ms. Wang Ying**

Ms. Wang Ying is a citizen in the PRC.

### **Beijing Leading Precision**

Beijing Leading Precision is a limited liability company established under the laws of the PRC. It is principally engaged in investment in the medical and healthcare industry. All the ultimate beneficial natural person owners of Beijing Leading Precision hold less than 30% of its equity interest, of which, the ultimate beneficial owner with the largest shareholding is Mr. Wang Lele, who holds approximately 6.19% equity interest.

## **Beijing Qihang**

Beijing Qihang is a limited liability partnership established under the laws of the PRC. It is principally engaged in investment management. The general partner of Beijing Qihang is Beijing QIHANG Venture Capital Management Co., Ltd. (all its ultimate beneficial natural person owners hold less than 30% of its equity interest, of which, the ultimate beneficial owner with the largest shareholding is Mr. Long Yibin, who holds approximately 22.70% equity interest) and all the ultimate beneficial natural person owners of Beijing Qihang hold less than 30% of its equity interest, of which, the ultimate beneficial owner with the largest shareholding is Mr. Long Yibin, who holds approximately 0.09% equity interest.

The Proposed Acquisition, if materialized, may constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules. The Company will make further announcements in due course in accordance with the requirements of the Listing Rules.

## **WARNING**

Shareholders of the Company should be aware that the Proposed Acquisition is still at the planning stage, the parties have not yet signed any definitive transaction agreements and the specific transaction proposals are still under discussion. The implementation of the Proposed Acquisition will be subject to, among other things, approval by the competent regulatory authorities and fulfilment of applicable requirements under the Listing Rules. There are still uncertainties as to whether any definitive agreements will be entered into or whether they will materialise or be completed.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Kindstar Globalgene Technology, Inc.**  
康聖環球基因技術有限公司  
**HUANG Shiang**  
*Chairman*

Hong Kong, March 27, 2024

*As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xiping and Mr. Gu Huaming as independent non-executive Directors.*

\* *For identification purpose only*